Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis.
Ortiz García
A M
AM
González-Alvaro
I
I
Roselló Pardo
R
R
Carmona
L
L
Fábregas Canales
M D
MD
Monteagudo Saez
I
I
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001168:Arthritis / Q000188:drug therapy*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D007555:Isoxazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000077339:Leflunomide
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D000069285:Infliximab; D000077339:Leflunomide